Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Ortega-Muro F"'
Autor:
Izat N; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Bolleddula J; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Abbasi A; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Cheruzel L; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Jones RS; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Moss D; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Ortega-Muro F; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Parmentier Y; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Peterkin VC; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Tian DD; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Venkatakrishnan K; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Zientek MA; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Barber J; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Houston JB; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Galetin A; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Scotcher D; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.) daniel.scotcher@manchester.ac.uk.
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Dec; Vol. 51 (12), pp. 1591-1606. Date of Electronic Publication: 2023 Sep 26.
Autor:
Sibley L; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK., White AD; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK., Sarfas C; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK., Gullick J; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK., Gleeson F; Department of Oncology, Medical Sciences Division, Churchill Hospital, Oxford OX3 7DQ, UK., Lanni F; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK., Clark S; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK., Rayner E; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK., Ferrer-Bazaga S; Departmento de Bioingenieria, Universidad Carlos III de Madrid, 28903 Madrid, Spain., Ortega-Muro F; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain., Alameda L; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain., Rullas J; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain., Sousa V; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain., Martinez M; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain., Angulo-Barturen I; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain., Garcia A; GlaxoSmithKlein, Research and Development, Diseases of the Developing World, Severo Ochoa, 2., 28760 Madrid, Spain., Vaquero JJ; Departmento de Bioingenieria, Universidad Carlos III de Madrid, 28903 Madrid, Spain., Pertinez HE; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 3GX, UK., Davies G; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 3GX, UK., Dennis M; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK., Williams A; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK., Sharpe S; UK Health Security Agency, Research and Evaluation, Porton Down, Salisbury SP4 0JG, UK.
Publikováno v:
Pharmaceutics [Pharmaceutics] 2022 Nov 30; Vol. 14 (12). Date of Electronic Publication: 2022 Nov 30.
Autor:
Muliaditan M; Clinical Pharmacology & Therapeutics Group, University College London, London, UK., Teutonico D; Translational Medicine and Early Development, Sanofi R&D, Chilly-Mazarin, France., Ortega-Muro F; GlaxoSmithKline Global Health Medicines Development Campus, Tres Cantos, Madrid, Spain., Ferrer S; GlaxoSmithKline Global Health Medicines Development Campus, Tres Cantos, Madrid, Spain., Della Pasqua O; Clinical Pharmacology & Therapeutics Group, University College London, London, UK; Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Brentford, UK. Electronic address: o.dellapasqua@ucl.ac.uk.
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2022 Jun 01; Vol. 173, pp. 106163. Date of Electronic Publication: 2022 Mar 04.
Autor:
Hu, Y, Pertinez, H, Ortega-Muro, F, Alameda-Martin, L, Liu, Y, Schipani, A, Davies, G, Coates, A
Currently, the most effective tuberculosis control method resides in case-finding and 6 months chemotherapy. There is a need to improve our understanding about drug interactions, combination activities and the ability to remove persistent bacteria in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::b8b8aba68020b7c5f1301951ef0c1ecb
Autor:
Barbieux, Emeline1,2 (AUTHOR), Potemberg, Georges1 (AUTHOR), Stubbe, François-Xavier3 (AUTHOR), Fraikin, Audrey1 (AUTHOR), Poncin, Katy1 (AUTHOR), Reboul, Angeline1 (AUTHOR), Rouma, Thomas1,2 (AUTHOR), Zúñiga-Ripa, Amaia4 (AUTHOR), De Bolle, Xavier1 (AUTHOR), Muraille, Eric1,2 (AUTHOR) emuraille@hotmail.com
Publikováno v:
PLoS Pathogens. 8/26/2024, Vol. 20 Issue 8, p1-29. 29p.
Autor:
Abla, Nada1 (AUTHOR) ablan@mmv.org, Almond, Lisa M.2 (AUTHOR), Bonner, Jennifer J.2 (AUTHOR), Richardson, Naomi3 (AUTHOR), Wells, Timothy N. C.1 (AUTHOR), Möhrle, Jörg J.1 (AUTHOR)
Publikováno v:
CTS: Clinical & Translational Science. Jul2024, Vol. 17 Issue 7, p1-11. 11p.
Autor:
Liu Y; Institute for Infection and Immunity, St George's, University of London, Cranmer Terrace, London SW17 ORE, UK., Pertinez H; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 3GF, UK., Ortega-Muro F; GlaxoSmithKline Research and Development, Diseases of Developing World, Severo Ochoa 2, 28760 Tres Cantos (Madrid), Spain., Alameda-Martin L; GlaxoSmithKline Research and Development, Diseases of Developing World, Severo Ochoa 2, 28760 Tres Cantos (Madrid), Spain., Harrison T; Institute for Infection and Immunity, St George's, University of London, Cranmer Terrace, London SW17 ORE, UK., Davies G; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 3GF, UK., Coates A; Institute for Infection and Immunity, St George's, University of London, Cranmer Terrace, London SW17 ORE, UK., Hu Y; Institute for Infection and Immunity, St George's, University of London, Cranmer Terrace, London SW17 ORE, UK.
Publikováno v:
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2018 Mar 01; Vol. 73 (3), pp. 724-731.
Autor:
Abrahams KA; Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Cox JAG; School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK., Fütterer K; Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Rullas J; Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo Ochoa 2, 28760, Tres Cantos, Madrid, Spain., Ortega-Muro F; Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo Ochoa 2, 28760, Tres Cantos, Madrid, Spain., Loman NJ; Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Moynihan PJ; Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Pérez-Herrán E; Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo Ochoa 2, 28760, Tres Cantos, Madrid, Spain., Jiménez E; Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo Ochoa 2, 28760, Tres Cantos, Madrid, Spain., Esquivias J; Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo Ochoa 2, 28760, Tres Cantos, Madrid, Spain., Barros D; Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo Ochoa 2, 28760, Tres Cantos, Madrid, Spain., Ballell L; Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo Ochoa 2, 28760, Tres Cantos, Madrid, Spain., Alemparte C; Tres Cantos Medicines Development Campus, GlaxoSmithKline, Severo Ochoa 2, 28760, Tres Cantos, Madrid, Spain. carlos.g.alemparte@gsk.com., Besra GS; Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. g.besra@bham.ac.uk.
Publikováno v:
Scientific reports [Sci Rep] 2017 Aug 25; Vol. 7 (1), pp. 9430. Date of Electronic Publication: 2017 Aug 25.
Autor:
Poce G; Dipartimento di Chimica e Tecnologie del Farmaco, 'Sapienza' Università di Roma, Rome, Italy. Electronic address: giovanna.poce@uniroma1.it., Consalvi S; Dipartimento di Chimica e Tecnologie del Farmaco, 'Sapienza' Università di Roma, Rome, Italy., Cocozza M; Dipartimento di Chimica e Tecnologie del Farmaco, 'Sapienza' Università di Roma, Rome, Italy., Fernandez-Menendez R; Diseases of the Developing World, Tres Cantos Medicines Development Campus, GSK, Tres Cantos, Madrid, Spain., Bates RH; Diseases of the Developing World, Tres Cantos Medicines Development Campus, GSK, Tres Cantos, Madrid, Spain., Ortega Muro F; Diseases of the Developing World, Tres Cantos Medicines Development Campus, GSK, Tres Cantos, Madrid, Spain., Barros Aguirre D; Diseases of the Developing World, Tres Cantos Medicines Development Campus, GSK, Tres Cantos, Madrid, Spain., Ballell L; Diseases of the Developing World, Tres Cantos Medicines Development Campus, GSK, Tres Cantos, Madrid, Spain., Biava M; Dipartimento di Chimica e Tecnologie del Farmaco, 'Sapienza' Università di Roma, Rome, Italy.
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2017 Mar 01; Vol. 99, pp. 17-23. Date of Electronic Publication: 2016 Dec 08.
Autor:
Hu Y; Institute for Infection and Immunity, St. George's, University of London, London, United Kingdom ymhu@sgul.ac.uk., Pertinez H; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Ortega-Muro F; GlaxoSmithKline Research and Development, Diseases of Developing World, Tres Cantos, Madrid, Spain., Alameda-Martin L; GlaxoSmithKline Research and Development, Diseases of Developing World, Tres Cantos, Madrid, Spain., Liu Y; Institute for Infection and Immunity, St. George's, University of London, London, United Kingdom., Schipani A; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Davies G; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Coates A; Institute for Infection and Immunity, St. George's, University of London, London, United Kingdom.
Publikováno v:
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2016 Jul 22; Vol. 60 (8), pp. 4778-85. Date of Electronic Publication: 2016 Jul 22 (Print Publication: 2016).